---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000045"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:59:24.301255+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Autolus restates 2021-2022 financials on R&D tax credit classification error

## Summary
- Error: UK SME R&D tax credits previously classified as income tax benefit should reduce R&D expense instead.
- Audit committee concluded non-reliance on FY2021 and FY2022 annual and interim financial statements on March 15, 2024.
- Restatement reduces income tax benefit by $24.6M (2022) and $24.0M (2021), with offsetting cuts to R&D expense; net loss unchanged.
- Company will correct error in upcoming 10-K for FY2023; no prior filings will be amended.

## SEC filing metadata
- accession: 0001730463-24-000045
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000045/0001730463-24-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000045/autl-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000045
- JSON: https://secwatch.observer/filing/0001730463-24-000045.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000045.txt

## Key facts
- Auditor Changes
  Autolus Therapeutics plc reported that prior financial statements should not be relied upon.
  - Action: non reliance
  - Auditor: Ernst & Young LLP
  source text: On March 15, 2024, the Audit Committee of the Company’s Board of Directors, upon the recommendation of the Company's management, and after discussion with the Company's independent registered public accounting firm, Ernst & Young LLP, concluded that the Company’s audited consolidated financial statements for the years ended December 31, 2022 and 2021, and the consolidated statements of operations for the quarterly periods in those years, as presented in the Company’s reports previously filed with the Securities and Exchange Commission (the “ SEC ”), should no longer be relied upon as a result of the foregoing error.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000045/0001730463-24-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.